Gilead Sciences has signed royalty-free license agreements allowing five generic drug firms to make and distribute its antiviral drug remdesivir in 127 countries The targeted countries are low income or “face significant obstacles to healthcare access,” Gilead says Supplies of the drug are severely limited;as of January, Gilead was not regularly making it The US gave emergency approval for remdesivir to treat COVID-19 at the end of April The firm has since been ramping up output, with the goal of supplying 1 million treatment courses by the end of 2020 Gilead describes remdesivir production as “a long, linear chemical synthesis process that must be completed sequentially and includes several specialized chemistry steps and novel substances with limited global availability ” The arrangement—with Cipla, Ferozsons Laboratories, Hetero, Jubilant Life Sciences, and Mylan—should increase global supply of remdesivir, Gilead says In addition to rights to the drug, Gilead will share its manufacturing,,,,